296 related articles for article (PubMed ID: 10460798)
21. Reconstitution of the enzymatic activities of cytochrome P450s using recombinant flavocytochromes containing rat cytochrome b(5) fused to NADPH--cytochrome P450 reductase with various membrane-binding segments.
Gilep AA; Guryev OL; Usanov SA; Estabrook RW
Arch Biochem Biophys; 2001 Jun; 390(2):215-21. PubMed ID: 11396924
[TBL] [Abstract][Full Text] [Related]
22. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
23. High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: influence of membrane charge.
Ingelman-Sundberg M; Hagbjörk AL; Ueng YF; Yamazaki H; Guengerich FP
Biochem Biophys Res Commun; 1996 Apr; 221(2):318-22. PubMed ID: 8619853
[TBL] [Abstract][Full Text] [Related]
24. Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.
Shet MS; Fisher CW; Holmans PL; Estabrook RW
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11748-52. PubMed ID: 8265621
[TBL] [Abstract][Full Text] [Related]
25. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
26. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4.
Lee CA; Kadwell SH; Kost TA; Serabjit-Singh CJ
Arch Biochem Biophys; 1995 May; 319(1):157-67. PubMed ID: 7771780
[TBL] [Abstract][Full Text] [Related]
27. Interaction of apo-cytochrome b5 with cytochromes P4503A4 and P45017A: relevance of heme transfer reactions.
Guryev OL; Gilep AA; Usanov SA; Estabrook RW
Biochemistry; 2001 Apr; 40(16):5018-31. PubMed ID: 11305918
[TBL] [Abstract][Full Text] [Related]
28. Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities.
Lee SJ; Goldstein JA
Drug Metab Pharmacokinet; 2012; 27(6):663-7. PubMed ID: 22785258
[TBL] [Abstract][Full Text] [Related]
29. Reconstitution of testosterone oxidation by purified rat cytochrome P450p (IIIA1).
Halvorson M; Greenway D; Eberhart D; Fitzgerald K; Parkinson A
Arch Biochem Biophys; 1990 Feb; 277(1):166-80. PubMed ID: 2106291
[TBL] [Abstract][Full Text] [Related]
30. Membrane properties induced by anionic phospholipids and phosphatidylethanolamine are critical for the membrane binding and catalytic activity of human cytochrome P450 3A4.
Kim KH; Ahn T; Yun CH
Biochemistry; 2003 Dec; 42(51):15377-87. PubMed ID: 14690448
[TBL] [Abstract][Full Text] [Related]
31. Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes.
Yamazaki H; Urano T; Hiroki S; Shimada T
J Toxicol Sci; 1996 Nov; 21(4):215-26. PubMed ID: 8959645
[TBL] [Abstract][Full Text] [Related]
32. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
Miyazaki M; Nakamura K; Fujita Y; Guengerich FP; Horiuchi R; Yamamoto K
Drug Metab Dispos; 2008 Nov; 36(11):2287-91. PubMed ID: 18669585
[TBL] [Abstract][Full Text] [Related]
33. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems.
Guengerich FP; Johnson WW
Biochemistry; 1997 Dec; 36(48):14741-50. PubMed ID: 9398194
[TBL] [Abstract][Full Text] [Related]
35. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
36. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Zhang ZY; King BM; Pelletier RD; Wong YN
Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities.
Nakajima M; Tane K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
J Pharm Sci; 2002 Apr; 91(4):952-63. PubMed ID: 11948533
[TBL] [Abstract][Full Text] [Related]
38. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
[TBL] [Abstract][Full Text] [Related]
39. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
Chiba M; Hensleigh M; Nishime JA; Balani SK; Lin JH
Drug Metab Dispos; 1996 Mar; 24(3):307-14. PubMed ID: 8820421
[TBL] [Abstract][Full Text] [Related]
40. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
Yamaori S; Yamazaki H; Suzuki A; Yamada A; Tani H; Kamidate T; Fujita Ki; Kamataki T
Biochem Pharmacol; 2003 Dec; 66(12):2333-40. PubMed ID: 14637191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
